



HEALTHCARE COOPERATIVE

# MEDICAL POLICY STATEMENT

## Wisconsin Marketplace

| Policy Name & Number                    | Date Effective |
|---|----------------|
| Facet Joint Interventions-WI MP-MM-1616 | 12/01/2024     |
| Policy Type                             |                |
| <b>MEDICAL</b>                          |                |

Medical Policy Statements are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased, or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage or Certificate of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other plan policies and procedures.

Medical Policy Statements do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage or Certificate of Coverage) for the service(s) referenced in the Medical Policy Statement. Except as otherwise required by law, if there is a conflict between the Administrative Policy Statement and the plan contract, then the plan contract will be the controlling document used to make the determination.

According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

### Table of Contents

|    |                               |   |
|----|-------------------------------|---|
| A. | Subject .....                 | 2 |
| B. | Background .....              | 2 |
| C. | Definitions .....             | 2 |
| D. | Policy .....                  | 3 |
| E. | Conditions of Coverage .....  | 5 |
| F. | Related Policies/Rules .....  | 5 |
| G. | Review/Revision History ..... | 5 |
| H. | References .....              | 5 |

## A. Subject

### **Facet Joint Interventions**

## B. Background

An estimated 84% of adults experience back pain during their lifetime. Long-term outcomes are largely favorable for most patients, but a small percentage of patients' symptoms persist. Persistent pain is categorized as subacute when it lasts between 4 and 12 weeks and chronic when it persists for at least 3 months. Facet joint pain comprises 27%-40% of patients with chronic low back pain (LBP).

Comprehensive pain management care plans are most effective in managing a patient's chronic pain. These plans focus on a person-centered approach and incorporate conservative treatment with other modalities. These multidisciplinary treatments promote patient self-management and aim to reduce the impact of pain on a patient's daily life, even if the pain cannot be relieved completely. In addition to conservative therapy, treatment options may include nonpharmacologic or pharmacologic treatments, and nonsurgical or surgical interventions. Only physicians qualified in interventional procedures for pain unresponsive to conservative treatment should perform these health services.

Most spinal structures may be the source of LBP, including intervertebral discs, facet joints, sacroiliac joints, and nerve roots. While some of these can be diagnosed by imaging, discogenic pain without disc herniation, facet joints, and sacroiliac joint pain are difficult to diagnose with imaging alone. Facet medial branch nerve blocks are a diagnostic tool to identify the cause of pain and can provide short term pain relief with certain medications. Following a presumptive diagnosis of facet joint pain through a physical examination and plain radiography or axial imaging, the diagnosis may be confirmed by relief of pain through injection of local anesthetic to the medial branches of the posterior rami of the dorsal spinal nerves supplying the proposed facet joint(s). Facet medial branch nerve blocks may be performed at the targeted joint itself, 1 joint above and 1 joint below on the same side, or bilaterally per treatment session. Facet medial branch nerve block injections should be performed with imaging guidance.

A patient may receive a diagnostic injection of a short-acting local anesthetic agent to identify the pain generator. If pain is relieved by the injection, then a radiofrequency ablation (RFA), which uses energy to destroy the nerve, can be performed. A successful radiofrequency facet ablation of the affected nerve (same anatomic location of the positive diagnostic block) may relieve pain for a period of months up to a year or more until nerve regeneration occurs.

## C. Definitions

- **Conservative Therapy** – A multimodality plan of care including both active and inactive conservative therapies.

- **Active Conservative Therapies** – Actions or activities that strengthen muscle groups and target key spinal structures, including physical therapy, occupational therapy, a physician supervised home exercise program (HEP), and/or chiropractic care.
  - **HEP** – A 6-week program requiring an exercise prescription and/or plan and a follow-up documented in the medical record after completion, or documentation of the inability to complete a HEP due to a stated physical reason (ie, increased pain, inability to physically perform exercises). Patient inconvenience or noncompliance without explanation does not constitute an inability to complete.
- **Inactive Conservative Therapies** – Passive activities by the patient that aid in treating symptoms associated with pain including rest, ice, heat, medical devices, acupuncture, TENS use, and/or pharmacotherapy (prescription or over the counter [eg, NSAIDS, acetaminophen]).
  - **Transcutaneous Electrical Nerve Stimulator (TENS)** – A device that utilizes electrical current directed through electrodes placed on the surface of the skin to decrease the patient’s perception of pain by inhibiting the transmission of afferent pain nerve impulses and/or stimulating the release of endorphins. Its use, frequency, duration, and start dates must be documented in the medical record to be considered part of conservative therapy.
- **Medial Branch Nerve Block Injection** – A diagnostic procedure in which a short-acting anesthetic (eg, lidocaine) is injected near small medial nerves connected to a specific facet joint. It may also be performed to treat back pain caused by facet joint(s) with a longer acting anesthetic (eg, bupivacaine).
  - **Successful Diagnostic Injection** – An injection that achieves greater than 80% reduction in pain within the duration of effectiveness for the anesthetic used.
- **Radiofrequency Ablation (RFA)** – Minimally invasive treatment modality that percutaneously introduces an electrode under fluoroscopic guidance to thermocoagulate medial branches of the dorsal spinal nerves.

#### D. Policy

Common Ground Healthcare Cooperative (CGHC) considers facet joint interventions for management of chronic back pain medically necessary when the clinical criteria in this policy are met. Documentation, including dates of service for conservative therapies, are not required for medical necessity review but must be available upon request.

##### I. Medial Branch Nerve Block Injections

- A. Up to 2 diagnostic medial branch nerve block injections in the cervical, thoracic, or lumbar regions are considered medically necessary when **ALL** of the following criteria are met:
  1. Initial diagnostic block confirms facet joint as source of spinal pain and provides 80% or greater primary pain relief and duration of relief is consistent with agent employed.

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

2. Second diagnostic block confirms validity of the initial injection and is injected at the same level where the initial produced a positive response.
  3. Each diagnostic block may treat up to 3 spinal levels (unilateral or bilateral) for a maximum of 6 spinal levels per spinal region per session.
  4. Radiofrequency ablation is being considered as a therapeutic intervention.
  5. Injections should be at least 2 weeks apart.
  6. Imaging studies and physical exam ruled out other causes of spinal pain (eg, fracture, tumor, infection, herniated disk, spinal stenosis, significant deformity).
  7. Patient history with at least 3 months of moderate to severe pain with functional impairment that has not adequately responded to active and inactive conservative therapy.
  8. Failure of conservative therapy as evidenced by **ALL** of the following:
    - a. Documentation in the medical record of at least 6 weeks of active conservative therapy (as defined above) within the past 6 months OR inability to complete active conservative therapy due to contraindication, increased pain, or intolerance.
    - b. Documentation in the medical record of at least 6 weeks of inactive conservative therapy (as defined above) within the past 6 months.
  9. There is no coagulopathy.
  10. There is no current infection at the injection site.
- B. Diagnostic medial branch nerve blocks are **NOT** considered medically necessary when RFA is not being considered as a treatment option.
- II. Radiofrequency Ablation (RFA) for Facet Joint Pain
- A. Initial RFA for facet joint pain is considered medically when in the past 36 months
    1. The clinical criteria above (I.A.1-10) have been met.
    2. 2 successful medial branch nerve block injections were performed at the same spinal region and achieved 80% or more pain relief.
  - B. Repeat RFA for facet joint pain is considered medically necessary when in the past 36 months
    1. Prior successful single or multilevel facet RFA in the same spinal region (cervical, thoracic, or lumbar) and side provided at least 50% pain relief over a minimum of 6 months.
    2. The most recent RFA was at least 6 months prior.
    3. No more than 4 RFAs per rolling 12 months (2 left and 2 right per spinal region) are considered appropriate.
- III. Sedation
- A. Neither conscious sedation nor monitored anesthesia care (MAC) is routinely necessary for intra-articular facet joint injections or medial branch blocks and are not routinely reimbursable.
  - B. Individual consideration may be given for payment in rare unique circumstances if the medical necessity of sedation is unequivocal and clearly documented.

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

IV. Inconclusive or Non-Supportive Evidence

- A. Medial branch nerve block injections are unproven for the treatment of chronic spinal pain. Routine therapeutic injections will not be authorized for chronic pain management.
- B. Intra-articular facet joint injections for neck and back pain are not considered medically necessary as there is limited evidence and the efficacy has not been established.
- C. Intra-articular facet joint injections do not qualify as diagnostic information for a proposed neurotomy.

V. Spinal Cord Stimulators/Pain Pumps

Patients with indwelling implanted spinal cord stimulators or pain pumps should include a device interrogation report with the required medical records for medical necessity review requests. If a device is not functioning properly, an escalation in pain may warrant evaluation and management of the implanted device.

E. Conditions of Coverage

NA

F. Related Policies/Rules

NA

G. Review/Revision History

| DATE                  |            | ACTION                            |
|-----------------------|------------|-----------------------------------|
| <b>Date Issued</b>    | 08/14/2024 | New market, approved at Committee |
| <b>Date Revised</b>   |            |                                   |
| <b>Date Effective</b> | 12/01/2024 |                                   |
| <b>Date Archived</b>  |            |                                   |

H. References

1. Ashmore ZM, Bies MM, Meiling JB, et al. Ultrasound-guided lumbar medial branch blocks and intra-articular facet joint injections: a systematic review and meta-analysis. *Pain Rep.* 2022;7(3):e1008. doi:10.1097/PR9.0000000000001008
2. Boswell MV, Manchikanti L, Kaye AD, et al. A best-evidence systematic appraisal of the diagnostic accuracy and utility of facet (zygapophysial) joint injections in chronic spinal pain. *Pain Physician.* 2015;18(4):E497-E533. Accessed June 17, 2024. [www.painphysicianjournal.com](http://www.painphysicianjournal.com)
3. Chou R. Subacute and chronic low back pain: nonsurgical interventional treatment. UpToDate. Update June 10, 2021. Accessed June 17, 2024. [www.uptodate.com](http://www.uptodate.com)
4. Chou R. Subacute and chronic low back pain: surgical treatment. UpToDate. Updated September 27, 2023. Accessed June 17, 2024. [www.uptodate.com](http://www.uptodate.com)

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

5. Chou R, Deyo R, Friedly J, et al. Nonpharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. *Ann Intern Med.* 2017;166(7):493-505. doi:10.7326/M16-2459
6. Cohen SP, Bhaskar A, Bhatia A, et al. Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. *Reg Anesth Pain Med.* 2020;45(6):424-467. doi:10.1136/rapm-2019-10124
7. Cohen SP, Moon JY, Brummett CM, et al. Medial branch blocks or intra-articular injections as a prognostic tool before lumbar facet radiofrequency denervation: a multicenter, case-control study. *Reg Anesth Pain Med.* 2015;40(4):376-383. doi:10.1097/AAP.0000000000000229
8. Copenhaver DJ, Pritzlaff SG, Jung M, et al. Interventional therapies for chronic pain. UpToDate. Updated April 16, 2024. Accessed April 25, 2024. www.uptodate.com
9. Curtis L, Shah N, Padalia D. Facet joint disease. *StatPearls.* StatPearls Publishing; updated January 9, 2023. Accessed June 17, 2024. www.ncbi.nlm.nih.gov
10. Facet Joint Injection. MCG Health. 28th ed. MCG Health; 2024. Updated March 14, 2024. Accessed June 17, 2024. www.careweb.careguidelines.com
11. Hurley RW, Adams MCB, Barad M, et al. Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group. *Reg Anesth Pain Med.* 2022;47(1):3-59. doi:10.1136/rapm-2021-103031
12. Isaac Z, Kelly H. Evaluation of the adult patient with neck pain. UpToDate. Updated May 31, 2023. Accessed June 17, 2024. www.uptodate.com
13. Le DT, Alem N. Facet Joint Injection. *StatPearls.* StatPearls Publishing; updated June 20, 2023. Accessed June 17, 2024. www.ncbi.nlm.nih.gov
14. Lee DW, Pritzlaff S, Jung MJ, et al. Latest Evidence-Based Application for Radiofrequency Neurotomy (LEARN): best practice guidelines from the American Society of Pain and Neuroscience (ASPN). *J Pain Res.* 2021;14:2807-2831. doi:10.2147/JPR.S325665
15. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive evidence-based guidelines for facet joint interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) guidelines facet joint interventions 2020 guidelines. *Pain Physician.* 2020;23(3S):S1-S127. Accessed June 17, 2024. www.painphysicianjournal.com
16. Perolat R, Kastler A, Nicot B, et al. Facet joint syndrome: from diagnosis to interventional management. *Insights Imaging.* 2018;9(5):773-789. doi:10.1007/s13244-018-0638x
17. Won HS, Yang M, Kim YD. Facet joint injections for management of low back pain: a clinically focused review. *Anesth Pain Med (Seoul).* 2020;15(1):8-18. doi:10.17085/apm.2020.15.1.8

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.